Showing results (61-70 of 229) with videos related to
Sort By:
Pageof 23
Clinical and Experimental Pharmacology & Physiology|March 1, 2008
Angiotensin converting enzyme 2 in the kidneyA Koitka, M E Cooper, M C Thomas, et al.Diabetes|April 1, 1993
The effects of perindopril and triple therapy in a normotensive model of diabetic nephropathyR C O'Brien, M E Cooper, G Jerums, et al.Kidney International|August 1, 1996
Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatmentT Soulis, M E Cooper, D Vranes, et al.Diabetologia|April 6, 2006
Anaemia in diabetes: Is there a rationale to TREAT?M C Thomas, M E Cooper, K Rossing, et al.Clinical and Experimental Pharmacology & Physiology|August 1, 1989
Ramipril reduces albuminuria in diabetic rats fed a high protein dietR C O'Brien, M E Cooper, T J Allen, et al.Clinical and Experimental Pharmacology & Physiology|September 1, 1986
Accelerated progression of diabetic nephropathy in the spontaneously hypertensive streptozotocin diabetic ratM E Cooper, T J Allen, G Jerums, et al.The American Journal of Physiology|February 12, 1998
Characterization of binding sites for amylin, calcitonin, and CGRP in primate kidneyS Y Chai, G Christopoulos, M E Cooper, et al.Diabetologia|December 29, 1998
Depletion of nitric oxide synthase-containing neurons in the diabetic retina: reversal by aminoguanidineE Roufail, T Soulis, E Boel, et al.Clinical and Experimental Pharmacology & Physiology. Supplement|January 1, 1992
Diabetic renal microvascular disease: the role of hypertension and ACE inhibitorsM E Cooper, J R Rumble, T Gin, et al.Journal of Hypertension|July 15, 1998
Angiotensin converting enzyme inhibition and calcium antagonism attenuate streptozotocin-diabetes-associated mesenteric vascular hypertrophy independently of their hypotensive actionZ Cao, U L Hulthén, T J Allen, et al.Pageof 23